CMPS rises after Compass says COMP360 benefits lasted up to a year
Compass Pathways said its experimental COMP360 psilocybin treatment continued to show benefits for some patients with treatment-resistant depression for up to a year.
Compass Pathways (CMPS) was in focus Wednesday after the company said its experimental psilocybin treatment COMP360 continued to show benefits in some patients with treatment-resistant depression for up to a year. COMP360 is Compass’ proprietary synthetic version of psilocybin.